⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
GSK News
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Disease-Modifying Therapies Market to Surpass USD 112.6 Billion by 2033 as Biologic Innovation Redefines Long-Term Disease Control
prnewswire.com
JNJ
ABBV
AZN
GSK
AMGN
Antibody Optimization Service Market Set to Reach USD 6.07 Billion by 2034, Growing at an 8.45% CAGR Amid Advances in Gene-Editing Technologies
globenewswire.com
ABBV
BMY
GILD
AMGN
AZN
LLY
BIIB
REGN
VRTX
XBI
IBB
CRSP
EDIT
NTLA
ABCL
NVS
MRK
PFE
JNJ
GSK
SNY
BTAI
INSM
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
businesswire.com
GSK
Pharma Supply Chain & Security World Returns to London: Building a Connected and Resilient Ecosystem
globenewswire.com
PFE
ALNY
BMY
NVS
GSK
Respiratory Inhaler Devices Market to Reach $51.9 billion, Globally, by 2034 at 4.8% CAGR: Allied Market Research
prnewswire.com
AZN
BIIB
TEVA
NVS
GSK
SUN
TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth
businesswire.com
VRTX
PTCT
GSK
Vertigo Drugs Market Outlook Report 2026-2034 - Landscape Shift Towards Targeted Drug Regimens Over Blanket Suppression, Emphasizing Early Rehab and Non-Sedating Prophylactics - ResearchAndMarkets.com
businesswire.com
ABT
SNY
PFE
GSK
NVS
New Report Urges Action to Ensure Sustainable, Affordable Supply of Key Vaccine Adjuvants for Global Health Use
prnewswire.com
GSK
NVAX
Diabetic Neuropathy Market Report: Trends, Forecast and Competitive Analysis to 2031 - APAC Leads Industry Growth as Demand for Pain Management Soars - ResearchAndMarkets.com
businesswire.com
PFE
JNJ
LLY
GSK
NVS
CData Recognized for Second Consecutive Year in the 2025 Gartner® Magic Quadrant™ for Data Integration Tools
prnewswire.com
GSK